BioNTech Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
BioNTech hat ein Gesamteigenkapital von €20.0B und eine Gesamtverschuldung von €2.3M, was einen Verschuldungsgrad von 0.01% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €22.3B bzw. €2.3B.
Wichtige Informationen
0.01%
Verhältnis von Schulden zu Eigenkapital
€2.30m
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | €15.67b |
| Eigenkapital | €19.97b |
| Gesamtverbindlichkeiten | €2.29b |
| Gesamtvermögen | €22.26b |
Jüngste Berichte zur Finanzlage
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09Recent updates
Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: BNTXDie kurzfristigen Aktiva des Unternehmens (€18.3B) übersteigen seine kurzfristigen Passiva (€1.6B).
Langfristige Verbindlichkeiten: BNTXDie kurzfristigen Vermögenswerte des Unternehmens (€18.3B) übersteigen seine langfristigen Verbindlichkeiten (€682.6M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: BNTX über mehr Barmittel verfügt als seine Gesamtverschuldung.
Schulden abbauen: BNTX Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 21.1% auf 0.01% zurückgegangen.
Schuldendeckung: BNTXDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (249195.7%).
Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von BNTX für seine Schulden durch das EBIT gut gedeckt sind.